Diagnosis

Ductal carcinoma in situ (DCIS)
. When DCIS is treated by breast conserving surgery, all subgroups of patients benefit from adjuvant radiation as well as from adjuvant tamoxifen [I, B]. Adjuvant tamoxifen for DCIS reduces the recurrence rate of in situ and of invasive breast cancer.
Primary systemic therapy
. Primary systemic therapy is indicated for inoperable locally advanced breast cancer (stage IIIB: T4, N2-3, regional M1)
. If possible it should be followed by both surgery and radiotherapy and postoperative systemic treatment. Primary systemic therapy is an alternative for large operable breast cancer, to allow breast conserving surgery [I, A].
Adjuvant systemic therapy
. Before deciding whether to use adjuvant systemic therapy, the prognosis without adjuvant therapy should be estimated. For each individual, the choice of adjuvant therapy must take into account the potential benefits, possible side effects, and patient preference. Literature
